A novel high performing multiplex immunoassay Multi-HTLV for serological confirmation and typing of HTLV infections.

<h4>Background</h4>Human T-Cell Lymphotropic Viruses (HTLV) type 1 and type 2 account for an estimated 5 to 10 million infections worldwide and are transmitted through breast feeding, sexual contacts and contaminated cellular blood components. HTLV-associated syndromes are considered as...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Lola Marqué, Peter Liehl, Jasper De Boer, Hans Pottel, Edward L Murphy, Roberta Bruhn, Mars Stone, Zhanna Kaidarova, Tzong-Hae Lee, Michael Busch, Maan Zrein
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2021
Materias:
Acceso en línea:https://doaj.org/article/ecd13555300a418899d39605bdd8a8cf
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:ecd13555300a418899d39605bdd8a8cf
record_format dspace
spelling oai:doaj.org-article:ecd13555300a418899d39605bdd8a8cf2021-12-02T20:23:32ZA novel high performing multiplex immunoassay Multi-HTLV for serological confirmation and typing of HTLV infections.1935-27271935-273510.1371/journal.pntd.0009925https://doaj.org/article/ecd13555300a418899d39605bdd8a8cf2021-11-01T00:00:00Zhttps://doi.org/10.1371/journal.pntd.0009925https://doaj.org/toc/1935-2727https://doaj.org/toc/1935-2735<h4>Background</h4>Human T-Cell Lymphotropic Viruses (HTLV) type 1 and type 2 account for an estimated 5 to 10 million infections worldwide and are transmitted through breast feeding, sexual contacts and contaminated cellular blood components. HTLV-associated syndromes are considered as neglected diseases for which there are no vaccines or therapies available, making it particularly important to ensure the best possible diagnosis to enable proper counselling of infected persons and avoid secondary transmission. Although high quality antibody screening assays are available, currently available confirmatory tests are costly and have variable performance, with high rates of indeterminate and non-typable results reported in many regions of the world. The objective of this project was to develop and validate a new high-performance multiplex immunoassay for confirmation and discrimination of HTLV-1 and HTLV-2 strains.<h4>Methodology/principal findings</h4>The multiplex platform was used first as a tool to identify suitable antigens and in a second step for assay development. With data generated on over 400 HTLV-positive blood donors sourced from USA and French blood banks, we developed and validated a high-precision interpretation algorithm. The Multi-HTLV assay demonstrated very high performance for confirmation and strain discrimination with 100% sensitivity, 98.1% specificity and 100% of typing accuracy in validation samples. The assay can be interpreted either visually or automatically with a colorimetric image reader and custom algorithm, providing highly reliable results.<h4>Conclusions/significance</h4>The newly developed Multi-HTLV is very competitive with currently used confirmatory assays and reduces considerably the number of indeterminate results. The multiparametric nature of the assay opens new avenues to study specific serological signatures of each patient, follow the evolution of infection, and explore utility for HTLV disease prognosis. Improving HTLV diagnostic testing will be critical to reduce transmission and to improve monitoring of seropositive patients.Lola MarquéPeter LiehlJasper De BoerHans PottelEdward L MurphyRoberta BruhnMars StoneZhanna KaidarovaTzong-Hae LeeMichael BuschMaan ZreinPublic Library of Science (PLoS)articleArctic medicine. Tropical medicineRC955-962Public aspects of medicineRA1-1270ENPLoS Neglected Tropical Diseases, Vol 15, Iss 11, p e0009925 (2021)
institution DOAJ
collection DOAJ
language EN
topic Arctic medicine. Tropical medicine
RC955-962
Public aspects of medicine
RA1-1270
spellingShingle Arctic medicine. Tropical medicine
RC955-962
Public aspects of medicine
RA1-1270
Lola Marqué
Peter Liehl
Jasper De Boer
Hans Pottel
Edward L Murphy
Roberta Bruhn
Mars Stone
Zhanna Kaidarova
Tzong-Hae Lee
Michael Busch
Maan Zrein
A novel high performing multiplex immunoassay Multi-HTLV for serological confirmation and typing of HTLV infections.
description <h4>Background</h4>Human T-Cell Lymphotropic Viruses (HTLV) type 1 and type 2 account for an estimated 5 to 10 million infections worldwide and are transmitted through breast feeding, sexual contacts and contaminated cellular blood components. HTLV-associated syndromes are considered as neglected diseases for which there are no vaccines or therapies available, making it particularly important to ensure the best possible diagnosis to enable proper counselling of infected persons and avoid secondary transmission. Although high quality antibody screening assays are available, currently available confirmatory tests are costly and have variable performance, with high rates of indeterminate and non-typable results reported in many regions of the world. The objective of this project was to develop and validate a new high-performance multiplex immunoassay for confirmation and discrimination of HTLV-1 and HTLV-2 strains.<h4>Methodology/principal findings</h4>The multiplex platform was used first as a tool to identify suitable antigens and in a second step for assay development. With data generated on over 400 HTLV-positive blood donors sourced from USA and French blood banks, we developed and validated a high-precision interpretation algorithm. The Multi-HTLV assay demonstrated very high performance for confirmation and strain discrimination with 100% sensitivity, 98.1% specificity and 100% of typing accuracy in validation samples. The assay can be interpreted either visually or automatically with a colorimetric image reader and custom algorithm, providing highly reliable results.<h4>Conclusions/significance</h4>The newly developed Multi-HTLV is very competitive with currently used confirmatory assays and reduces considerably the number of indeterminate results. The multiparametric nature of the assay opens new avenues to study specific serological signatures of each patient, follow the evolution of infection, and explore utility for HTLV disease prognosis. Improving HTLV diagnostic testing will be critical to reduce transmission and to improve monitoring of seropositive patients.
format article
author Lola Marqué
Peter Liehl
Jasper De Boer
Hans Pottel
Edward L Murphy
Roberta Bruhn
Mars Stone
Zhanna Kaidarova
Tzong-Hae Lee
Michael Busch
Maan Zrein
author_facet Lola Marqué
Peter Liehl
Jasper De Boer
Hans Pottel
Edward L Murphy
Roberta Bruhn
Mars Stone
Zhanna Kaidarova
Tzong-Hae Lee
Michael Busch
Maan Zrein
author_sort Lola Marqué
title A novel high performing multiplex immunoassay Multi-HTLV for serological confirmation and typing of HTLV infections.
title_short A novel high performing multiplex immunoassay Multi-HTLV for serological confirmation and typing of HTLV infections.
title_full A novel high performing multiplex immunoassay Multi-HTLV for serological confirmation and typing of HTLV infections.
title_fullStr A novel high performing multiplex immunoassay Multi-HTLV for serological confirmation and typing of HTLV infections.
title_full_unstemmed A novel high performing multiplex immunoassay Multi-HTLV for serological confirmation and typing of HTLV infections.
title_sort novel high performing multiplex immunoassay multi-htlv for serological confirmation and typing of htlv infections.
publisher Public Library of Science (PLoS)
publishDate 2021
url https://doaj.org/article/ecd13555300a418899d39605bdd8a8cf
work_keys_str_mv AT lolamarque anovelhighperformingmultipleximmunoassaymultihtlvforserologicalconfirmationandtypingofhtlvinfections
AT peterliehl anovelhighperformingmultipleximmunoassaymultihtlvforserologicalconfirmationandtypingofhtlvinfections
AT jasperdeboer anovelhighperformingmultipleximmunoassaymultihtlvforserologicalconfirmationandtypingofhtlvinfections
AT hanspottel anovelhighperformingmultipleximmunoassaymultihtlvforserologicalconfirmationandtypingofhtlvinfections
AT edwardlmurphy anovelhighperformingmultipleximmunoassaymultihtlvforserologicalconfirmationandtypingofhtlvinfections
AT robertabruhn anovelhighperformingmultipleximmunoassaymultihtlvforserologicalconfirmationandtypingofhtlvinfections
AT marsstone anovelhighperformingmultipleximmunoassaymultihtlvforserologicalconfirmationandtypingofhtlvinfections
AT zhannakaidarova anovelhighperformingmultipleximmunoassaymultihtlvforserologicalconfirmationandtypingofhtlvinfections
AT tzonghaelee anovelhighperformingmultipleximmunoassaymultihtlvforserologicalconfirmationandtypingofhtlvinfections
AT michaelbusch anovelhighperformingmultipleximmunoassaymultihtlvforserologicalconfirmationandtypingofhtlvinfections
AT maanzrein anovelhighperformingmultipleximmunoassaymultihtlvforserologicalconfirmationandtypingofhtlvinfections
AT lolamarque novelhighperformingmultipleximmunoassaymultihtlvforserologicalconfirmationandtypingofhtlvinfections
AT peterliehl novelhighperformingmultipleximmunoassaymultihtlvforserologicalconfirmationandtypingofhtlvinfections
AT jasperdeboer novelhighperformingmultipleximmunoassaymultihtlvforserologicalconfirmationandtypingofhtlvinfections
AT hanspottel novelhighperformingmultipleximmunoassaymultihtlvforserologicalconfirmationandtypingofhtlvinfections
AT edwardlmurphy novelhighperformingmultipleximmunoassaymultihtlvforserologicalconfirmationandtypingofhtlvinfections
AT robertabruhn novelhighperformingmultipleximmunoassaymultihtlvforserologicalconfirmationandtypingofhtlvinfections
AT marsstone novelhighperformingmultipleximmunoassaymultihtlvforserologicalconfirmationandtypingofhtlvinfections
AT zhannakaidarova novelhighperformingmultipleximmunoassaymultihtlvforserologicalconfirmationandtypingofhtlvinfections
AT tzonghaelee novelhighperformingmultipleximmunoassaymultihtlvforserologicalconfirmationandtypingofhtlvinfections
AT michaelbusch novelhighperformingmultipleximmunoassaymultihtlvforserologicalconfirmationandtypingofhtlvinfections
AT maanzrein novelhighperformingmultipleximmunoassaymultihtlvforserologicalconfirmationandtypingofhtlvinfections
_version_ 1718374140643115008